CSF2 and malignant mesothelioma: Other groups have used autologous tumor cells (malignant mesothelioma) in combination with repeated subcutaneous injections of recombinant GM-CSF (80 μg) failing to induce major tumor regression despite inducing tumor-specific immunity in 32% of patients [27].